Talis Biomedical Corporation
TLIS
$1.60
-$0.08-4.76%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 32.11% | 3.16% | 14.17% | -4.31% | 15.69% |
| Total Depreciation and Amortization | -67.94% | 24.17% | -2.76% | 29.17% | -3.45% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -65.31% | 319.89% | -66.74% | 14.08% | 90.60% |
| Change in Net Operating Assets | -1,350.13% | -20.90% | 1,016.67% | 101.33% | -307.09% |
| Cash from Operations | -76.29% | 43.41% | -1.91% | 21.93% | 13.31% |
| Capital Expenditure | -- | -- | 232.86% | 85.57% | -1,920.83% |
| Sale of Property, Plant, and Equipment | 180.00% | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 180.00% | -67.74% | 232.86% | 85.57% | -1,920.83% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -- | -- | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.00% | -- | -- | -- | -100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -75.86% | 43.23% | -0.45% | 24.02% | 10.31% |
